Advanced search
Publication Cover
Emerging Microbes & Infections Volume 1, 2012 - Issue 1
Submit an article Journal homepage
1,264
Views
34
CrossRef citations to date
0
Altmetric
Reviews

‘ZS-MDR-TB’ versus ‘ZR-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility

Ying Zhang1 Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA;2 Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, ChinaCorrespondence[email protected]
,
Kwok Chiu Chang3 Tuberculosis and Chest Service, Department of Health, Hong Kong, China
,
Chi-Chiu Leung3 Tuberculosis and Chest Service, Department of Health, Hong Kong, China
,
Wing Wai Yew4 Department of Microbiology, Chinese University of Hong Kong, Hong Kong, China
,
Brigitte Gicquel5 Unite de Génétique Mycobactérienne, Institut Pasteur, 28 rue du Dr. Roux 75015 Paris, France
,
Dorothy Fallows6 Laboratory of Mycobacterial Immunity and Pathogenesis, Public Health Research Institute at University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA
,
Gilla Kaplan6 Laboratory of Mycobacterial Immunity and Pathogenesis, Public Health Research Institute at University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA
,
Richard E Chaisson7 Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA
&
Wenhong Zhang2 Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China
 show all
Pages 1-4 | Received 13 Apr 2012, Accepted 12 Jun 2012, Published online: 25 Jan 2019

  • WHO. WHO report 2010: Global Tuberculosis Control;2010.
  • Anti-tuberculosis Drug Resistance in the World, Report No, 4. 2008. Available at http://www.who.int/tb/publications/2008/en/index.html (accessed 13 March 2012).
  • Zhang Y, Mitchison D.The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis2003;7: 6–21.
  • Mitchison DA.The action of antituberculosis drugs in short course chemotherapy. Tubercle1985;66: 219–225.
  • Nuermberger E, Tyagi S, Tasneen R et al.Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother2008;52: 1522–1524.
  • Rosenthal IM, Zhang M, Williams KN et al.Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med2007;4: e344.
  • Andries K, Verhasselt P, Guillemont J et al.A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science2005;307: 223–227.
  • Ibrahim M, Andries K, Lounis N et al.Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother2007;51: 1011–1015.
  • Diacon AH, Pym A, Grobusch M et al.The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med2009;360: 2397–2405.
  • McCune RM Jr, McDermott W, Tompsett R.The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med1956;104: 763–802.
  • McCune RM, Feldmann FM, Lambert HP, McDermott W.Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med1966;123: 445–468.
  • Hong Kong TB Treatment Service/British Medical Research Council.Controlled trial of 8-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. Tubercle1975;56: 81–96.
  • Hong Kong TB Treatment Service/British Medical Research Council.Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months. Am Rev Respir Dis1977;115: 727–735.
  • Mitnick C, Bayona J, Palacios E et al.Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med2003;348: 119–128.
  • van Deun A, Maug AK, Salim MA et al.Short, highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med2010;182: 684–692.
  • Chang KC, Yew WW, Zhang Y.Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother2011;55: 4499–4505.
  • Leung E, Yew W, Leung C, Leung W, Tam C.Shorter treatment duration for selected patients with multidrug-resistant tuberculosis. Eur Respir J2011;38: 227–230.
  • Migliori GB, Besozzi G, Girardi E et al.Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J2007;30: 623–626.
  • Simpson G, Coulter C, Weston J et al.Resistance patterns of multidrug-resistant tuberculosis in Western Province, Papua New Guinea. Int J Tuberc Lung Dis2011;15: 551–552.
  • Senol G, Coskun M, Gunduz AT, Bicmen C, Gayaf M, Ozsoz A.[Investigation of pyrazinamide resistance in multidrug-resistant tuberculosis cases in Hospital of Pulmonary Diseases, Izmir, Turkey]. Mikrobiyoloji Bulteni2008;42: 591–597. Turkish.
  • Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A.Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol2010;10: 223.
  • Minime-Lingoupou F, Pierre-Audigier C, Kassa-Kelembho E et al.Rapid identification of multidrug-resistant tuberculosis isolates in treatment failure or relapse patients in Bangui, Central African Republic. Int J Tuberc Lung Dis2010;14: 782–785.
  • Louw GE, Warren RM, Donald PR et al.Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis2006;10: 802–807.
  • Ando H, Mitarai S, Kondo Y et al.Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan. Clin Microbiol Infect2010;16: 1164–1168.
  • Chiu YC, Huang SF, Yu KW, Lee YC, Feng JY, Su WJ.Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan. BMC Infect Dis2011;11: 240.
  • Rao NA, Irfan M, Soomro MM, Mehfooz Z.Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients. J Coll Physicians Surg Pak2010;20: 262–265.
  • Kim HJ, Kwak HK, Lee J et al.Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea. Int J Tuberc Lung Dis2012;16: 98–103.
  • Shenai S, Rodrigues C, Sadani M, Sukhadia N, Mehta A.Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing. Indian J Tuberc2009;56: 82–90.
  • Pierre-Audigier C, Surcouf C, Cadet-Daniel V et al.Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis. Int J Tuberc Lung Dis2012;16: 221–223, i–ii.
  • Aragon LM, Garrigo M, Moreno C, Espanol M, Coll P.Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide. J Antimicrob Chemother2007;60: 655–657.
  • Hewlett D Jr, Horn DL, Alfalla C.Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA1995;273: 916–917.
  • Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F.Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol2010;48: 300–301.
  • Miller MA, Thibert L, Desjardins F, Siddiqi SH, Dascal A.Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. J Clin Microbiol1995;33: 2468–2470.
  • Zhang Y, Permar S, Sun Z.Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol2002;51: 42–49.
  • Brander E.A simple way of detecting pyrazinamide resistance. Tubercle1972;53: 128–131.
  • Martin A, Takiff H, Vandamme P, Swings J, Palomino JC, Portaels F.A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother2006;58: 327–331.
  • Mirabal NC, Yzquierdo SL, Lemus D et al.Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis. J Clin Microbiol2010;48: 2729–2733.
  • Martin A, Cubillos-Ruiz A, von Groll A, del Portillo P, Portaels F, Palomino JC.Nitrate reductase assay for the rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother2008;61: 123–127.
  • McClatchy JK, Tsang AY, Cernich MS.Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob Agents Chemother1981;20: 556–557.
  • Scorpio A, Zhang Y.Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med1996;2: 662–667.
  • Scorpio A, Lindholm-Levy P, Heifets L et al.Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother1997;41: 540–543.
  • Cheng SJ, Thibert L, Sanchez T, Heifets L, Zhang Y.pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother2000;44: 528–532.
  • Huang TS, Lee SS, Tu HZ et al.Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrobial Agents and Chemotherapy2003;47: 3672–3673.
  • Sreevatsan S, Pan X, Zhang Y, Kreiswirth BN, Musser JM.Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother1997;41: 636–640.
  • Somoskovi A, Dormandy J, Parsons LM et al.Sequencing of the pncA gene in members of the Mycobacterium tuberculosis complex has important diagnostic applications: identification of a species-specific pncA mutation in ‘Mycobacterium canettii’ and the reliable and rapid predictor of pyrazinamide resistance. J Clin Microbiol2007;45: 595–599.
  • Zhang H, Deng JY, Bi LJ et al.Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase. Febs J2008;275: 753–762.
  • Sheen P, Ferrer P, Gilman RH et al.Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb)2009;89: 109–113.
  • Lemaitre N, Callebaut I, Frenois F, Jarlier V, Sougakoff W.Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis. Biochem J2001;353( Pt 3): 453–458.
  • Shi W, Zhang X, Jiang X et al.Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science2011;333: 1630–1632.
  • Jureen P, Werngren J, Toro JC, Hoffner S.Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy2008;52: 1852–1854.
  • Wade MM, Volokhov D, Peredelchuk M, Chizhikov V, Zhang Y.Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray. Diagn Microbiol Infect Dis2004;49: 89–97.
  • Zhou M, Geng X, Chen J et al.Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method. PLoS One2011;6: e27654.
  • Sekiguchi J, Nakamura T, Miyoshi-Akiyama T et al.Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. J Clin Microbiol2007;45: 2802–2807.
  • Simons SO, van Ingen J, van der Laan T et al.Validation of pncA gene sequencing in combination with the MGIT method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol2012;50: 428–434.
  • Chang KC, Leung CC, Yew WW, Lau TY, Tam CM.Hepatotoxicity of pyrazinamide: cohort and case–control analyses. Am J Respir Crit Care Med2008;177: 1391–1396.
  • Stover CK, Warrener P, VanDevanter DR et al.A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature2000;405: 962–966.
  • Gler MT, Skripconoka V, Sanchez-Garavito E et al.Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med2012;366: 2151–2160.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.